Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Phase II Study: MSCs in Inflammation-Resolution Programs of SARS-CoV-2 Induced ARDS

NCT04377334 is registered in ClinicalTrials.gov with University Hospital Tuebingen as lead sponsor.

NCT NCT04377334
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04377334 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Phase II Study: MSCs in Inflammation-Resolution Programs of SARS-CoV-2 Induced ARDS
Lead sponsor
University Hospital Tuebingen
Phase
Phase 2
Overall status
Unknown status
Start date
May 31, 2022
Completion date
February 28, 2023
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ards, covid-19